Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evidence-informed decision-making process of the National Essential Medicines List Committee and Essential Drugs Programme.

Journal of the colleges of medicine of South Africa·2026
Same author

A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Healthy Adults.

Clinical pharmacology in drug development·2026
Same author

Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data.

Clinical and translational science·2026
Same author

Ethics and equity in access to disease-modifying therapies and newborn screening for spinal muscular atrophy: A scoping review.

Developmental medicine and child neurology·2026
Same author

Severe lithium-induced nephrogenic diabetes insipidus: The diuresis paradox.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2025
Same author

A systematic review and meta-analysis of noradrenaline compared to adrenaline in the management of septic shock.

African journal of emergency medicine : Revue africaine de la medecine d'urgence·2025

Related Experiment Video

Updated: Jun 26, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

Heparin-induced thrombocytopaenia.

Ronald Gounden1, Marc Blockman

  • 1Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa. ronald.gounden@uct.ac.za

Cardiovascular Journal of Africa
|December 24, 2008
PubMed
Summary

Heparin-induced thrombocytopaenia (HIT) is a temporary blood disorder caused by heparin, leading to both low platelet counts and clot formation. Management focuses on non-heparin anticoagulants to address the prothrombotic state.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: Jun 26, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

  • Hematology
  • Vascular Biology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopaenia (HIT) is an acquired disorder.
  • It is characterized by a prothrombotic state and decreased platelet count.
  • HIT is a significant complication associated with heparin therapy.

Purpose of the Study:

  • To elucidate the pathophysiology of heparin-induced thrombocytopaenia.
  • To explain the paradoxical coexistence of thrombosis and thrombocytopaenia in HIT.
  • To highlight the importance of non-heparin antithrombotic agents in managing HIT.

Main Methods:

  • Review of existing literature on HIT.
  • Analysis of the mechanisms underlying heparin's effects on platelets and coagulation.
  • Synthesis of clinical data regarding HIT management strategies.

Main Results:

  • HIT creates a prothrombotic environment despite falling platelet counts.
  • The mechanism involves heparin triggering platelet activation and aggregation.
  • Thrombosis is a primary clinical manifestation of HIT.

Conclusions:

  • Heparin-induced thrombocytopaenia is a complex disorder with a dual effect on platelets and thrombosis.
  • Understanding the prothrombotic milieu is key to managing HIT.
  • Non-heparin antithrombotic therapies are essential for effective HIT treatment.